Teva has given up on a key trial of one of its original lineup of innovative medicines. | Teva has given up on a key trial of ...
The PASI 90 rate, which is in line with the phase 2 result, looks competitive. Cross-trial comparisons can be unreliable, ...
The FDA has put a partial hold on Biosciences’ seizure study application over preclinical toxicity data and concerns about ...
Tiziana Life Sciences’ intranasal drug has hit the dual endpoints of a phase 2a study in patients with a form of multiple sclerosis (MS), although the win was slightly marred by the higher dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results